Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million

globenewswire.com
PFE Pfizer Inc. reported significant positive results from a Phase 2 study of Ponsegromab, showing increased body weight and muscle mass, leading to plans for registration-enabling studies. This indicates strong potential for their cachexia treatment. MRK Merck & Co. Inc. is mentioned as a market leader in the cancer cachexia sector. The article does not provide specific details about their current performance or future outlook within this market. ABBV AbbVie Inc. is listed as a dominating company in the cancer cachexia market. However, the article does not offer specific details regarding their recent performance or future prospects in this sector. AZN AstraZeneca plc is identified as a key player and market leader in the cancer cachexia market. The article does not provide specific performance data or future outlook for the company in this context. SNY Sanofi SA is mentioned as a market leader in the cancer cachexia sector. The article does not provide any specific information about their performance or future outlook related to this market.

Cancer Cachexia Market Outlook Report 2026-2030: Personalized Treatments and Digital Tools Elevate Cancer Cachexia Care; Total Revenue to Grow by $600 Million Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Cancer Cachexia Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides critical insights, including market size statistics, regional shares, competitive landscape, and emerging opportunities, essential for stakeholders aiming to navigate the complex dynamics of the cancer cachexia industry.

The cancer cachexia market has shown robust growth recently, expanding from $2.6 billion in 2025 to an anticipated $2.75 billion in 2026, at a CAGR of 5.8%. This progression is driven by factors such as increased late-stage cancer diagnoses, enhanced management awareness, and the early adoption of anabolic agents. Looking ahead, the market forecasts indicate growth to $3.35 billion by 2030, with an expected CAGR of 5.1%. Factors like personalized treatment demand, advancements in research, outpatient service expansion, and digital monitoring adoption contribute to this development.

Substantial market trends include increased use of combination drug regimens, muscle preservation therapies, nutritional supplementation strategies, and advancements in anti-inflammatory treatments. Enhanced cachexia progression monitoring is also pivotal. Rising global cancer rates act as a catalyst for market expansion, spurred by lifestyle changes, environmental factors, and an aging population. Technological advancements and improved diagnostic techniques result in more frequent cachexia diagnoses, allowing for earlier intervention and treatment.

Prominent companies in the sector are focusing on developing targeted therapies, including monoclonal antibodies, to improve patient outcomes by mitigating muscle and weight loss associated with cachexia. In September 2024, Pfizer Inc. reported significant positive results from a Phase 2 study of Ponsegromab, which targets GDF-15, demonstrating increased body weight and muscle mass, leading to plans for registration-enabling studies in 2025. Similarly, LG Chem Ltd.'s acquisition of AVEO Oncology in January 2023 marks strategic diversification in cancer treatment offerings.

Dominating the market are industry leaders such as Pfizer Inc., Merck & Co. Inc., AbbVie Inc., AstraZeneca plc, and Sanofi SA. In 2025, North America was identified as the largest regional market. However, Asia-Pacific is projected to experience the fastest growth. The assessment covers vital regions including Asia-Pacific, Western Europe, North and South America, and others, with specific attention on major countries like the USA, China, India, and Brazil.

Report Scope

Discover the largest, fastest, and most rapidly evolving sectors within the cancer cachexia market. Understand the market's connection to global economic trends and other sectors. Key forces discussed include technological disruptions, regulatory changes, and consumer preferences.

Coverage

Analyze the market by therapeutics, mechanisms of action, and distribution channels covering subsegments in progestogens, corticosteroids, combination therapies, and other therapeutics. Key companies like Pfizer, Merck, and AstraZeneca are profiled, alongside markets including the USA, Germany, and China. The report features historical and forecast data from key regions worldwide, utilizing a wealth of data for comprehensive market analysis.

Key Attributes

The companies featured in this Cancer Cachexia market report include:

For more information about this report visit https://www.researchandmarkets.com/r/kyp7ao

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment